|Podcasts|September 24, 2021

Dr. Sarah Faris on taking precautions when prescribing postoperative opioids

“Opioids are opioids…they can lead to long-term usage regardless of their FDA class. We really need to be good stewards for our patients,” says Sarah F. Faris, MD.

In this episode, Urology Times® Managing Editor Ben Saylor spoke with Sarah F. Faris, MD. She discusses the recent Urology study, “Persistent Opioid Usage After Urologic Intervention and the Impact of Tramadol,” and how clinicians need to take precaution when prescribing opioids for postoperative care. Faris is an associate professor of surgery at the University of Chicago, Illinois.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Dr. Sarah Faris on taking precautions when prescribing postoperative opioids

Related Content

The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD

Pearls & Perspectives: The Evolving Landscape of Female Pelvic Health, With Annah J. Vollstedt, MD

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

Pearls & Perspectives: Expanding Options for Men With Erectile Dysfunction, With Tom Riester

Pearls & Perspectives: Understanding the Peptide Movement in Men’s Health, with Larry I. Lipshultz, MD

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Urology Times

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC

ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer